Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C24H33N3O6 and a molecular weight of approximately 459.5 g/mol. It is classified as an alpha amino acid derivative but does not have any approved medical indications or known clinical use. The drug has been listed in chemical and pharmaceutical databases as an experimental compound, but there are no reported mechanisms of action, targets, or therapeutic applications in humans. No information on its pharmacological activity or development status for any disease is available[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{4-[2-(1A,7A-dimethyl-4-oxy-octahydro-1-oxa-4-aza-cyclopropa[a]naphthalen-4-yl)-acetylamino]-phenylcarbamoyl}-butyric acid.